Zymeworks Announces Participation in Upcoming Conferences
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-dru
(Financial Post, 2025-12-02T21:05:52Z)